The future of decentralized clinical trials in an evolving EU regulatory landscape

Webinar On Demand

The COVID-19 pandemic has demonstrated the feasibility of adapting clinical trials from site-based endeavors to fully decentralized or hybrid models and has increased global acceptance of decentralized trials as a safe and effective option for accelerating clinical research. Enabled by digital, technological, and logistical innovations, decentralized clinical trials offer advantages that will endure beyond the pandemic.

In this webinar, your will learn from our experts Aruna Talapatra and Scott Emery, as they review the regulatory and geographic factors that can influence the adoption of DCTs, and it will provide a roadmap for implementing decentralized clinical trials within the current legal environment in Europe. Specifically, the presentation will address the critical importance of the following: 

  • A robust and secure technology architecture for trial related data acquisition, storage, and communication
  • A drug distribution and management strategy that meets all stability, storage, and dosing access and administration requirements
  • A high-level understanding of the evolving EU regulatory landscape to ensure compliance with good clinical practice (GCP) requirements and all relevant legislation